Inozyme Pharma (INZY) Stock Price, News & Analysis

Company Overview

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $4.00 to $4.00
• 50-Day Range: $3.95 to $4.00
• 52-Week Range: $0.72 to $6.24
• Volume: N/A
• Average Volume: 960,267 shs
• Market Capitalization: $258.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.75
• Consensus Rating: Hold

INZY Stock Analysis - Frequently Asked Questions

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.01.

When did Inozyme Pharma IPO?

Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Inozyme Pharma's major shareholders?

Top institutional investors of Inozyme Pharma include Beryl Capital Management LLC (9.79%), Alpine Associates Management Inc. (3.39%), Affinity Asset Advisors LLC (2.71%) and Gabelli Funds LLC (2.26%). Insiders that own company stock include Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Henric Bjorn Bjarke and Douglas A Treco.
View institutional ownership trends.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), CocaCola (KO), Meta Platforms (META), QUALCOMM (QCOM) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INZY
• CIK: 1693011
• Web: www.inozyme.com
• Phone: 857-330-4340
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Inozyme Pharma: $11.75
• High Price Target: $23.00
• Low Price Target: $4.00
• Potential Upside/Downside: +193.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$102.02 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -159.93%
• Return on Assets: -82.48%

Debt

• Debt-to-Equity Ratio: 0.65
• Current Ratio: 2.19
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 4.44

Miscellaneous

• Outstanding Shares: 64,562,000
• Free Float: 56,698,000
• Market Cap: $258.25 million
• Optionable: Optionable
• Beta: 2.27